As pressure mounts on pharma companies to accelerate therapeutic drug development for patients with moderate to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as a vaccine for its prevention, we are supporting and driving patient-centric COVID-19 therapeutic treatment clinical trials; with 7 active trials covering Novel NCEs and Existing Drugs in two countries, across 70+ sites, with some 1,700+ patients, we can partner with you to achieve better outcomes.

Read our latest case studies and learn how, for two global companies, we are driving operational approaches to evaluate the safety and efficacy of their therapies to both moderate and severe COVID-19 patients. From being awarded the studies to date we have:

• Quickly activated sites within 20 and 15 days respectively
• Achieved FPI in 30 and 15 days respectively
• Accomplished 100% on-time completion of key milestones
• Comprehensive trial oversight through our in-house analytics platform

Please complete the form to download our case studies.

© 2020 Navitas Life Sciences | Privacy Policy